臺灣博碩士論文加值系統

全球的癌症婦女內有12%為子宮頸癌。 在西元2004年台灣的統計當中，子宮頸癌排名十大癌症死亡原因的第七名，同時亦是女性癌症十大癌症死亡原因的第五名。 根據許多研究顯示出子宮頸癌患者有超過90%以上含有人類乳突瘤病毒核酸，其中最常見的是血清型第16型和血清型第18型。 E6和E7致癌蛋白質，兩種非結構性病毒蛋白，對於細胞的轉型已有很完整的了解，而L1蛋白質為病毒外殼結構蛋白質。 因此選定此三個的抗原，作為血清學研究的依據。 本實驗室已對25位病患經臨床診斷罹患子宮頸癌的病患，確認感染人類乳突瘤病毒血清型第18型，並且於病灶組織偵測L1和E6抗原已有初步的結果。 目前血清學的研究對第18型的了解較不齊全，因此針對第18型進行血清學的研究。 利用免疫酵素連結吸附檢測法測量25位病患和22位正常個體血清抗E6和抗L1抗體之研究亦有初步的結果。 因此本實驗將針對人類乳突瘤病毒血清型第18型中的非結構性蛋白質E7進行探討。 E7蛋白質在病毒生活史中病毒生產時期扮演重要的角色。 此外E7蛋白質可以和pRb相互作用，解除對細胞週期的調控,造成細胞的轉型。 利用西方墨點法已偵測到多數子宮頸癌病人腫瘤組織和相對正常組織含有血清型第18型E7抗原的表現。 另外，使用穀胱苷肽轉移酶接合系統表達選定的病毒蛋白，而表達出的GST-E7蛋白質作為抗原來偵測先前提及的血清其抗GST-E7抗體的結合能力。 25位病患抗GST-E7的表現顯著高於22位正常個體。 這些結果說明受到人類乳突瘤病毒感染的子宮頸癌病患中，不論在病人的病灶位置或是相對正常位置皆顯示出E7的抗原表現。 另外也觀察出子宮頸病患血清中具有較高結合能力的抗血清型第18型E7非結構性蛋白質抗體，可能做為未來研究潛在的診斷標記分子。

Cervical cancer accounts for almost 12% of all cancers in women globally. The statistical information in 2004, cervical cancer is the seventh leading cause of death in Taiwan, and the fifth leading cause of death among major cancers in women. According to the previous studies, at least 90% of the cervical cancer patients contain human papillomavirus (HPV) DNA, and types -16 and -18 are the most common one of HPV. Therefore, we will focus on the HPV-18 serological study. E6 and E7 oncoproteins, two viral nonstructural proteins, are involved in cell transformation, and L1 is the viral structural protein. These three antigens were selected for serological studies. Our laboratory had detected HPV-18 L1 and E6 antigens in cervical tissue from 25 patients with clinically confirmed cervical cancer and the HPV serotype was identified as the type 18. Currently, the serological information of HPV-18 was rare. The binding of the anti-E6 and anti-L1 antibody from 25 patients and 22 normal individuals had been measured by enzyme-linked immunosorbent assay previously. In this study, we focus on the nonstructural protein, the E7 protein of HPV-18. The E7 plays a critical role in the productive stage of the viral cycle. It also can interact with pRb resulting in abrogation of cell cycle that caused cell transformation. In my works, most patients expressed the E7 antigen in tumor tissue and their normal counter part assayed by Western blot. We also used glutathione S-transferase (GST) fusion system to express the HPV-18 E7 viral proteins in E. coli. The GST-E7 fusion protein was used as antigens to measure the binding of anti-E7 antibody in sera. The expression of anti-E7 antibody in 25 patients is significant higher than the 22 normal individuals. These result shows both in patients’ tissue part and normal counter part containing the E7 antigen. Also, the higher binding of anti-E7 antibody observed in the patients’ sera indicated that the anti-E7 antibody may also be a potential marker for diagnosis in the future.

目錄
目錄------------------------------------------------------- 1
中文摘要--------------------------------------------------- 3
英文摘要--------------------------------------------------- 4
前言------------------------------------------------------- 5
人類乳突瘤病毒感染與環境因素---------------------------- 5
人類乳突瘤病毒的特性------------------------------------ 5
人類乳突瘤病毒的分類------------------------------------ 6
人類乳突瘤病毒生活史------------------------------------ 7
人類乳突瘤病毒致病機制---------------------------------- 7
人類乳突瘤病毒引發的免疫機轉---------------------------- 8
人類乳突瘤病毒血清學研究-------------------------------- 10
材料與方法-------------------------------------------------- 13
子宮頸癌組織與血清-------------------------------------- 13
穀胱苷肽轉移酶基因接合係統------------------------------ 13
聚合酶連鎖反應-------------------------------------- 14
勝任細胞的備製-------------------------------------- 15
質體重組與轉型作用---------------------------------- 15
重組質體的純化與濃度的檢測-------------------------- 16
重組質體方向性的確認-------------------------------- 17
重組蛋白質的表達------------------------------------ 17
重組蛋白質的純化------------------------------------ 18
子宮頸癌組織蛋白質的萃取-------------------------------- 19
蛋白質濃度的測定---------------------------------------- 19
蛋白質電泳分析------------------------------------------ 20
蛋白質電泳膠體染色-------------------------------------- 20
西方轉漬法---------------------------------------------- 21
酵素連結免疫吸附檢測法---------------------------------- 23
組織染色------------------------------------------------ 23
免疫組織染色---------------------------------------- 23
結果-------------------------------------------------------- 25
一、子宮頸組織HPV-18 E7抗原的研究------------------------ 25
免疫組織染色---------------------------------------- 25
西方點墨法------------------------------------------ 25
二、聚合酶酵素連鎖反應與重組質體方向性確認--------------- 25
三、重組蛋白質的表達與純化------------------------------- 26
四、子宮頸癌病人中抗HPV-18 E7抗體的研究------------------ 27
討論-------------------------------------------------------- 28
參考文獻---------------------------------------------------- 34
圖表目錄---------------------------------------------------- 40
結果(圖)---------------------------------------------------- 41
附圖---------------------------------------------------- 54
附表---------------------------------------------------- 58
個人資料---------------------------------------------------- 60

Ahmad, H., Medh, R. D., Singh, S. V., Caccuri, A. M., Ansari, G. A. and Awasthi, Y. C. (1989). Anionic glutathione S-transferase of human erythrocytes. Enzyme, 42,129-35.
Ahn, W. S., Bae, S. M., Kim, T. Y., Kim, T. G., Lee, J. M., Namkoong, S. E., Kim, C. K. and Sin, J.I. (2003). A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum. Gene Ther., 14, 1389-1399.
Awasthi, Y. C., Dao, D. D. and Saneto, R. P. (1980). Interrelationship between anionic and cationic forms of glutathione S-transferase of human liver.
Baldwin, P., Laskey, R. and Coleman, N. (2003). Translational approaches to improving cervical screening. Nature Rev. Cancer, 3, 217-225.
Bosch, F. X., Lorincz, A., Munoz, N., Meijer C. J. L. M., and Shah K. V. (2002). The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol., 55, 244-265.
Birnboim, H. C. and Doly, J. (1979). Arapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acid Res., 7, 1513-1523.
Blachon, B., and Demeret, C. (2003). The regulatory E2 protein of human genital papillomaviruses are pre-apoptotic. Biochimie, 85, 813-819.
Burd. E. M. (2003). Human papillomavirus and cervical cancer. Clin. Microbiol. Rev., 26, 1-17.
Chang, C. H., Chen, T. H., Hsu, R. C., Chou, P. H.,Yang, J. J., and Hwang, G. Y. (2005). The prevalence of HPV-18 and variants of E6 gene isolated from cervical cancer patients in Taiwan. J. Clin. Virol., 32, 33-37.
Chee, Y. H., Namkoong, S. E., Kim, D. H., Kim, S. J., and Park, J. S. (1995). Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins. Gynecol. Oncol., 57, 226-231.
Corden, S. A., Sant-Cassia, L. J., Easton, A. J., and Morris, A. G. (1999). The integration of HPV-18 DNA cervical carcinoma. J. Clin. Pathol. Mol Pathol., 52, 275-282.
Dao, D. D., Partrdige, C. A., Kursoky, A. and Awasthi, Y. C. (1984). Human glutathione S-transferase characterization of the anionic forms from lung and placenta. Biochem. J., 221, 33-41.
Doorbar J. (2005) The papillomavirus life cycle. J. Clin. Virol., 32S, S7-S15.
Ferenczy, A., and Franco, E. (2002). Persistent human papillomavirus infection and cervical neoplasia. The Lancet Oncol. 3, 11-16.
Fisher, S., G., Benitenz-Briviesca, L., Nindl, I., Stockfleth, E., Müller, M., Wolf, H., Perez-Garica, F., Guzman-Gaona, J., Gutierrez-Delgado, F., Irvin, W., and Gissmann, L. (1996). The association of human papillomavirus type E6 and E7 antibody with stage of cervical cancer. Gynecol. Oncol. 61, 73-78.
Frazer, I. H. (2004). Prevention of cervical cancer through papillomavirus vaccination. Nature Rev. Immunol., 4, 46-54
Fujii, T., Matsushima, Y., Yamjima, M., Sugimura, T. and Terada, M. (1995). Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients. Jpn. J. Cancer Res., 86, 28-34.
Ho, C. M., Yang, S. S., Chien, T. Y., Huang, S. H., Jeng, C. J and Chang, S. F. (2005). Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol. Oncol., 99, 615-621.
Ho, G. Y. F., Bierman, R., Beardsley, L., Chang, C. J., and Burk, R. D. (1998). Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338, 423-428.
Ho, G. Y. F., , Studentsov, Y. Y., Bierman, R. and Burk, R. D. (2004). Natural history of Human papillomavirus type 16 Virus-Like Particle antibody in young women. Cancer Epidemiol. Biomarkers Prev. 13, 110-116.
Inoue, H., Nojima, H. and Okayama, H. (1990). Hign efficiency transformation of Escherichia coli with plasmid. Gene, 96, 23-28.
Jochmus-Kudielka, I., Schneider, A., Braun, R., Kimmig, R., Koldovsky, U., Schneweis, K. E., Seedorf, K. and Gissmann, L. (1989). Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J. Natl. Cancer Inst., 81, 1698-1704.
Kay, P., Allan, B., Denny, L., Goffman, M. and Williamson, A. L. (2005). Detection of HPV 16 and HPV 18 DNA in blood of patients with cervical cancer. J. Med. Virol. 75, 435-439.
Klaes, R., Woerner, S. M., Ridder, R., Wentzensen, N., Duerst, M., Schneider, A., Lotz, B., Melsheimer, P. and von Kenbel Doeberitz, M. (1999). Detection of high-risk cervical intraepitheal neoplasia and cervical caner by amplification of transcripts derived from integrated papillomavirus onconges. Cancer Res., 59, 6132-6236.
Kyhse-Andersen, J. (1984). Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J. Biochem. Biophys. Methods, 10, 203-9.
Lehtinen, M., Leminen, A., Paavonen, J., Lehtovirta, P., Hyöty, H., Vesterinen E., and Dillner, J. (1992). Predominance of serum antibodies to synthetic peptide stemming from HPV-18 open reading frame E2 in cervical adenocarcinoma. J. Clin. Pathol. 45, 494-497.
Lonardo, A. D., Marcante, M. L., Poggiali, F., and Venuti, A. (1998). HPV 16 E7 antibody levels in cervical cancer patients: Before and after treatment. J. Med. Virol., 54, 192-195.
Lowy, D. R., and Schiller, J. T. (2006). Prophylactic human papillomavirus vaccines. J. Clin. Invest., 116, 1167-1173.

Mahdavi, A. and Monk, B. J. (2005). Vaccines against human papillomavirus and cervical cancer: Promises and challenges. The oncologist, 10, 528-538.
Matsumoto, K., Yoshikawa, H., Yasugi, T., Nakagawa, S., Kawana, K., Takeoka, A., Yaegashi, N., Iwasaka, T., Kanazawa, K., Taketani,Y. and Kanda, T. (2003). IgG antibody to human papillomavirus 16, 52, 58 and 6 L1 capsids: Case-control study of cervical intraepithelial neoplasia in Japan. J. Med. Virol., 69, 441-446.
McLaughlin-Drubin, M. E., Bromberg-White, J. L., and Meyers C. (2005). The role of the human papillomavirus type 18 E7 oncoprotin during the complete viral life cycle. Virology., 338, 61-68.
Meschede, W., Zumvach, K., Braspenning, J., Scheeffner, M., Benitez-Bribiesca, L., Luande. J., Gissmann, L., and Pawlita, M. (1998). Antibodies against early proteins of human papillomavirus as diagnostic marker for invasive cervical cancer. J. Clin. Microbio., 36, 475-480.
Molijn, A., Kleter, B., Quint, W., and van Doorn, L. J. (2005). Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol., 32S, S43-S51.
Munger, K., and Howley, P. M. (2002). Human papillomavirus immortalization and transformation functions. Virus Res., 89, 213-228.
Nicol, A. F., Fernandes, A. T. G., Bonecini-Almeida, M. da G.. (2005). Immune response in cervical dysplasia induced by human papillomavirus: the influence of human immunodeficiency virus-1 co-infection. Mem. Inst. Oswaldo. Cruz., 100, 1-12.
Park, J., S. Park, D., C., Kim, C., J., Ahn, H., K., Um, S., J., Park, S., N., Kim, S., N., and Namkoong, S., E. (1998). HPV-16-Related protein as the serologic markers in cervical neoplasia. Gynecol. Oncol. 69, 47-55.
Psyrri, A., DeFilippis, R. A., Edward, A. P. B., Yates, K. E., Manuelidis, L., and DiMaio, D. (2004). Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Res., 64, 3079-3086.
Rocha-Zavaleta, L., Ambrosio, J. P., Mora-Garcia, M. de L., Cruz-Talonia, F., Hernandez-montes, J., Weiss-Steider, B., Ortiz-Navarrete, V. and Monoroy-Garcia, A. (2004). Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions. J. General Virol., 85, 2643-2650.
Rosales, R., Lopez-Contreras, M., and Cortes, R., R. (2001). Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: Correlation with presence of papillomavirus DNA. J. Med. Virol. 65, 736-744.
Sathish, N., Abraham, P., Peedicayil, A., Sridharan, G., John, S., Shaji, R. V. and Chandy, G. (2004). HPV DNA in plasma of patients with cervical carcinoma. J. Clin. Virol., 31, 204-209.
Schiffman, M., and Philip, E. C. (2005). The Promise of Global Cervical-Cancer Prevention. N. Engl. J. Med., 353, 2101-2104.
Sehr, P., Zumbach, K., and Pwalita, M. (2001). A generic capture ELISA for recombinant protein fused to glutathione S-transferase: validation for HPV serology. J. Immuno. Method, 253, 153-162.
Sehr, P., Muller, M., Hopfl, R., Widschwendter, A., Pawlita, M. (2002). HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J. Virol. Method. 106, 61-70.
Smith, D. B., and Johnson, K. S. (1988). Single-step purification of polypeptides expressed in Escherichia coli as fusion with glutathione S-transferase. Gene, 67, 31-40.
Steel, R. D. G., Torrie, J. H. and Dickey, D. A. (1997). Principles and procedures of statistics, 3rd ed. New York: McGraw-Hill, Inc. p191.
Sun, Y., Eluf-Neto, J., Bosch, F. X., Muñoz, N., Walboomers, J. M. M., Meijer, C. J. L. M., Shah, K. V., Clayman, B. and Viscidi, R. P. (1999). Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma. Cancer Epidemiol. Biomarkers Prev. 8, 935-940.
Wang, S. S., Schiffman, M., Shields, T. S., Herrero, R., Hildesheim, A., Bratti, M. C., Sherman, M. E., Rodriguez, A. C., Castle, P. E., Morales, J., Alfaro, M., Wright, T., Chen, S., Clayman, B., Burk, R. D., and Viscidi, R. P. (2003). Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br. J. Cancer, 89, 1248-1254.
Wang, S. S., Schiffman, M., Herrero, R., Carreon, J., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., Sherman, M. E., Morales, J., Guillen, D., Alfaro, M., Clayman, B., Burk, R. D., and Viscidi, R. P. (2004). Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10000 women in Costa Rica. Br. J. Cancer, 91, 1269-1274.
Wilson, C. M. (1979). Studies and critique of Amido Black 10B, Coomassie Blue R, and Fast Green FCF as stains for proteins after polyacrylamide gel electrophoresis. Anal Biochem. 15, 263-78.
Womack, S. D., Chirenje, Z. M., Gaffikn, L., Blumenthal, P. D., McGrath, J. A., Chipato, T., Ngwalle, S., Munjoma, M and Shah, K. V. (2000). HPV-based cervical cancer screening in a population at high risk for HIV infection. Int. J. Cancer, 85, 206-210.
Zumbach, K., Kisseljov, F., Sacharova, O., Shaichav, G., Semjonova, L., Pavlova, L., and Pawlita, M. (2000). Antibodies against oncoproteins E6 and E7 of Human papillomavirus type 16 and 18 in cervical-carcinoma patients from Russia. Int. J. Cancer, 85, 313-318.
zur Hausen, H. (2002). Papillomaviruses and cancer: From basic studies to clinical application. Nature Rev. cancer, 2, 342-350.